Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $49.5 million.

  • Spyre Therapeutics' Total Liabilities fell 4716.7% to $49.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $49.5 million, marking a year-over-year decrease of 4716.7%. This contributed to the annual value of $90.7 million for FY2024, which is 2373.1% up from last year.
  • Per Spyre Therapeutics' latest filing, its Total Liabilities stood at $49.5 million for Q3 2025, which was down 4716.7% from $83.1 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Total Liabilities peaked at $253.6 million during Q2 2023, and registered a low of $18.8 million during Q1 2023.
  • Its 5-year average for Total Liabilities is $61.5 million, with a median of $49.5 million in 2025.
  • In the last 5 years, Spyre Therapeutics' Total Liabilities soared by 102450.11% in 2023 and then crashed by 7567.5% in 2024.
  • Spyre Therapeutics' Total Liabilities (Quarter) stood at $26.0 million in 2021, then decreased by 19.8% to $20.8 million in 2022, then soared by 251.69% to $73.3 million in 2023, then grew by 23.73% to $90.7 million in 2024, then tumbled by 45.41% to $49.5 million in 2025.
  • Its last three reported values are $49.5 million in Q3 2025, $83.1 million for Q2 2025, and $87.2 million during Q1 2025.